Bioconjugate Highly Potent Materials Handling - Abzena

Highly Potent API (HPAPI) Development & Manufacturing

Abzena accelerates HPAPI development and manufacturing with proven high-potency expertise, advanced containment technologies, and integrated chemistry-to-GMP capabilities, delivering scalable solutions for complex payloads, linkers, and bioconjugates.

Many of today’s most promising therapies rely on highly potent compounds, but developing and manufacturing HPAPIs requires specialist expertise, containment, and scalability. Abzena helps de-risk and accelerate HPAPI programs with more than 20 years of high-potency experience, combining advanced chemistry, dedicated containment infrastructure, and integrated development and GMP manufacturing capabilities. From payload design and process optimization to clinical and commercial supply, Abzena enables you to move your most complex molecules forward with confidence and speed.

Contact Us

Supporting the scale-up of your high potency APIs (HPAPIs), we offer unique, specialist, large-scale high potency capabilities from a dedicated manufacturing facility in Bristol, PA.

As highly potent payloads become increasingly central to next-generation bioconjugates and ADCs, Abzena provides the expertise needed to transform scientific potential into clinical success. With deep experience in HPAPI development, specialist facilities, and integrated chemistry-to-manufacturing capabilities, we help streamline development, reduce risk, and accelerate the journey from discovery to commercialization. Our payload resources include a toolbox of highly potent cytotoxic payloads (HPAPIs) with different mechanisms of action for use in the development of Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCS) and other complex bioconjugates.

In addition, Abzena can design and synthesize custom combinations of potent cytotoxic payloads and linkers or provide guidance and advise on selection of payloads.

HPAPI Capabilities

Capabilities

  • Up to 5 g of compounds with OELs of 1-10 ng/m3 in our research labs
  • >1 kg of compounds with OELs of 1-10 ng/m3 in our high potency process labs​
  • >1 kg of compounds with OELs of 1-10 ng/m3 in our small molecule cGMP suite

We have engineering controls​ to support your program which include:

  • Dedicated laboratories with a focus on cytotoxic containment​
  • Independent air-handling (HVAC) system; HEPA-filtered ventilation​
  • Enclosed and HEPA-ventilated weighing stations​
  • Isolator glove boxes in all cytotoxic containment laboratories​
  • Use of PPE (Powered Air Purifying Respirators) with single-use full-body suits​
Contact Us

Case Study: AOC GMP Manufacturing for a First-in-Human Study

Integrated Bioconjugate & ADC Development Services - Abzena

Abzena successfully supported a customer developing an Antibody-Oligonucleotide Conjugate (AOC) by providing integrated development and GMP manufacturing expertise to advance the program toward a first-in-human (FIH) clinical study. Leveraging our end-to-end bioconjugation capabilities, including complex chemistry, analytical support, process development, and GMP manufacturing, Abzena helped accelerate the program while reducing development and scale-up risk for the client.

This program highlights Abzena’s ability to manage complex bioconjugate development and manufacturing challenges through integrated scientific, technical, and GMP capabilities – depth and expertise that is equally critical when progressing highly potent payloads, linker-payloads, ADCs, and other advanced bioconjugates from development into clinical manufacturing.

Read Case Study

Payload Expertise and Development Support

Abzena has experience supporting a broad range of highly potent payload classes for targeted therapeutics, including auristatins, maytansines, duocarmycins, PBD dimers, camptothecins and anthracyclines. Combined with linker payload design and bioconjugation expertise, our teams help optimize payload selection, develop scalable synthetic routes and support successful technology transfer into GMP manufacturing.

Why Partner with Abzena for HPAPI Development?

Abzena Bristol - Hero

As highly potent payloads become increasingly important in ADCs and other bioconjugates, Abzena has the integrated development and manufacturing capabilities, and proven scale-up experience to help accelerate programs, reduce risk, and support a seamless path from early development through commercial supply.

Key advantages for Abzena’s HPAPI handling include:

  • Fully integrated chemistry-to-GMP support
  • Specialist containment infrastructure
  • Bioconjugate and ADC expertise
  • Risk reduction through early development
  • Commercial scale-up capabilities
  • Regulatory and technology transfer support
Contact Us

HPAPI Handling FAQs

What is a highly potent API (HPAPI)?

A highly potent API (HPAPI) is a highly active compound used in advanced therapeutics, including ADCs and other bioconjugates, that requires specialized expertise, containment, and manufacturing controls to develop and produce safely

What containment levels can Abzena support?

Abzena can support compounds with occupational exposure limits (OELs) of 1–10 ng/m³ in its research laboratories, high-potency process laboratories, and small molecule cGMP suites using dedicated containment infrastructure and engineering controls.

Can Abzena manufacture HPAPIs for ADC programs?

Yes, Abzena provides integrated HPAPI development and manufacturing services for ADCs, AOCs, and other bioconjugates, including payload, linker-payload, and bioconjugate production.

How does Abzena support scale-up from development to GMP manufacture?

Abzena supports scale-up through process development, optimization, technology transfer, analytical support, and clinical-to-commercial GMP manufacturing designed to ensure robust and consistent production.

Can Abzena support custom payload synthesis?

Yes, Abzena can design and synthesize custom combinations of cytotoxic payloads and linkers, as well as provide guidance on payload selection for ADCs and other complex bioconjugates

What analytical testing capabilities support HPAPI development?

Abzena supports HPAPI development with analytical method development, product characterization, release testing, stability testing, and monitoring of critical quality attributes to support development and GMP manufacturing.

Related Content

Linker Payload Design & Synthesis

Supporting your candidate ranking and lead selection process, we determine the optimal design of linker payload architecture and profiling in a series of in silico, ...

Learn More

Process Development & Optimization

Our experts collaborate together to develop quality, commercially viable processes ensuring seamless scale up through to commercial launch.

Learn More

Technology Transfer

We utilize a comprehensive risk-based approach to ensure a successful technology transfer by capturing process knowledge throughout your program and incorporating any regulatory authority feedback ...

Learn More

Bioconjugate Clinical Through Commercial cGMP Manufacturing

We are experienced in offering reliable, predictable clinical to commercial cGMP bioconjugates & ADC manufacturing.

Learn More

Antibody-Drug Conjugates (ADCs) Development

Discover the leading end-to-end ADC CDMO partner from design to development and manufacture.

Learn More

Antibody-Drug Conjugate Manufacturing

We offer integrated development and manufacturing services across the ADC components: antibodies, linker payloads, and bioconjugation.

Learn More

Let’s move medicine forward.

The treatments you’re developing right now can make a real difference for human health. Let us use our expertise in designing and synthesizing highly potent cytotoxic payloads, biological payloads, and linker-payload reagents to create tailored solutions for your next project.

Contact Us